

References

References

- Aaronson NK, Cull AN, Kaasa S, Sprangers MA et al.,(2002):** Stem cell transplantation: Quality of life and pharmacoeconomics-In spilker B ed. Lippincott-Raven: 179-189.
- Aaronson, N.K. (1991):** Methodologic issues in assessing the QOL of cancer patients cancer 67; 844-850.
- Abdelhai, R (2000):** Bronchial asthma: A study among attendants of children's hospital, Cairo university. M. Sc. Public health, faculty of medicine, Cairo University.
- Acosta JR. Jeffrey Lotz, Ph. D., Christopher P. Ames, M.D. (2005):** the potential role of mesenchymal stem cell therapy for intervertebral disc degeneration: A Critical Overview Neurosurg Focus. 19(3).
- Akahoshi M, Takanashi M, and Masuda M (1992):** A case of transfusion associated graft versus host disease not prevented by white cell- reduction filters. Transfusion 32: 169-172.
- Almeida-Porada G, Porada CD, Chamberlain J et al., (2004):** Formation of human hepatocytes by human haematopoietic stem cells in sheep. Blood 104: 2582-90.
- Amrolia P, Gasper HB, Hassan A et al., (2000):** Non myeloablative stem cell transplantation for congenital immuno-difficiencies. Blood 96: 1239-46.
- Anasetti C, Martin PJ, & Storb R (1992):** Treatement of acute graft-versus host disease with a non mitogenic anti- CD3 monoclonal antibody. Transplantation 54: 844-851.
- Anderson KC, Goodnough LT and Sayer SM (1991):** Variation in blood components irradiation practice: implications for prevention of T-GVHD. Blood 77: 2095-2102.

- Anderson TC and Weinstein HJ, (1990):** Transfusion-associated graft versus-host –disease. N Engl J Med. 323: 315-321.
- Andreani M, Nesci S, Lucarelli G, Tonucci P, Rapa S, Angelucci E, et al., (2000):** Long term survival of ex-thalassemic patients with persistent mixed chimerism after bone marrow transplantation. Bone Marrow transplant; 25: 401-4.
- Antin JH, and Ferrara JLM (1992):** Cytokine dysregulation and acute graft-versus host disease. Blood 80 (12): 2964- 2968.
- Appelbaum FR. (1990):** Bone Marrow transplantation for acute nonlymphocytic leukemia (ANL) cancer treat res; 50: 201-22.
- Aristei C, Alessandro M. Santucci A, et al., (2001):** Cataracts in patients receiving stem cell transplantation after conditioning with total body irradiation. Bone Marrow transplant: March; (29)(6): 503-507.
- Asakura, A. and Rudnicki, M.A. (2002):** Side population cells from diverse adult tissues are capable of in vitro hematopoietic differentiation. Exp. Hematol. 30: 1339-1345.
- Ashcan J, Ringelen O and Andstrom E, (1994):** Individualized prophylaxis against graft- versus host disease in leukemic marrow transplant recipient. Bone Marrow transplantation 14: 79-87.
- Atkinson. K. (editor) (2000):** Clinical Bone Marrow and blood Stem cell Transplantation, 2nd ed. Cambridge, Cambridge University Press.
- Bacigalupo A (2004):** Mesenchymal stem cells and haematopoietic stem cell transplantation. Clinical haematology 17: 387-99.
- Bacigalupo A, Mailino A and Van Lint MT (1990):** Cyclosporin A & Chronic graft-versus –host disease. Bone Marrow transplant 6: 341-344.

- Bailey AS, Jiang S, Afetnoulis M et al., (2004):** Transplanted adult haematopoietic stem cells differentiate into functional endothelial cells. *Blood* 103: 13-19.
- Bajwa RP, Cant AJ, Abinun M et al. (2003):** Recombinant tissue plasminogen activator for treatment of hepatic veno-occlusive disease following bone marrow transplantation. *Bone marrow transplantation* 31, 591-597.
- Ballard B (1991):** Renal and hepatic complications. In Whedon, M. (Ed.) *Bone Marrow Transplantation: Principles, Practice, and Nursing Insights*. Boston: Jones & Bartlett, 241-261.
- Barker, S. K; Wagner, J. E (2003):** Umbilical cord blood transplantation for the treatment of cancer. *3(7):* 526-532.
- Bashey A, Cormghan S, Gilpin E.(2000):** Simultaneous administration of G- CSF and GM- CSF for re-mobilization in patients with inadequate initial progenitor cell collection for autologous transplantation. *Cytotherapy* 2: 195- 201.
- Bearman SI, Appelbaum FR, and Buckner CD (1988):** Regimen related toxicity in patients undergoing bone marrow transplantation. *J. Clin Oncol.* 6: 1562-1568.
- Beatty PG, Clift RA, and Mickelson EM (1985):** Marrow transplantation from related donors other than HLA-identical siblings. *N Eng. J Med*, 313 (13): 765-771.
- Bellingham RE (1996):** The biology of graft –versus host disease. In: *The harrey lectures*. New York: Academic press, 62: 21-78 (caught).
- Benito AI, Diaz MA, Gonzalez M, Sevilla J, and Maderol (2004):** Hematopoietic stem cell transplantation using umbilical cord blood progenitors: review of current clinical results. *Bone Marrow Tarnsplantation* 33,675-695.

- Bennett ST, Johnson NL, Lasky LC. (1992):** Quality assurance and standards in hematopoietic progenitor processing. *J Clin Apheresis*. 7 (3): 138-44.
- Bensinger WI, Martin PJ, Storer B et al., (2001):** Transplantation of bone marrow as compared with peripheral blood cells from HLA identical relatives in patients with hematology cancers. *N. Eng. J. Med*. 344, 175-81.
- Bianco, P.; Riminucci, M.; Grothos, S. and Gehron, P. (2001):** Bone marrow stromal cells: nature, biology, and potential applications. *Stem cells*, 19 (3): 180-192.
- Bjornson, C.R.; Rietze, R.L. and Reynolds, A.B. (2000):** Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. *Science, J. Clin. Invest.*, 105: 1663-1668.
- Blayney DW, Le Blank ML, Grogan T et al., (2003):** Dose-intense chemotherapy every 2 weeks with dose-intense cyclophosphamide, doxorubicin, vincristine, and prednisone may improve survival in intermediate- and high-grade lymphoma: a phase II study of the southwest Oncology Group (SWOG 9349). *Journal of Clinical Oncology* 21: 2466-73.
- Boobis A, Rawlins M, Thomas S, and Wilkins M (1999):** Cyclophosphamide. In Dollery C (ed.): *Therapeutic Drugs*, 2nd edition, Vol. 1. New York: Churchill Livingstone, 349-354.
- Bornhauser M, Kiehl M, Sigert W, et al., (2000):** Dose-reduced conditioning for allorafting in 44 pateints with chronic myeloid leukemia: a tretrospective analysis. *British Journal of Haematology* 115: 119-24.
- Bortin MM, Horowitz MM, and Rinn AA (1992):** Increased utilization of allogeneic bone marrow transplantation. *Ann Intern Med*. 116: 505-512.

- Boulad F; Sands S; Sklar C (1998):** Late complications after bone marrow transplantation in children and adolescents. *Curr probl pediatri*, 28 (9): p 273-97.
- Bowling, A. (2003):** Social research on health: Sociological & psychological concepts and approaches. In, *Research methods in health: investigating health & In, health services*. A. Bowling (Ed). 2nd edition. Maidenhead, England, Open University. Press.
- Bowling; A. (1997):** Measuring health. A review of quality of life measurement scales. 2nd edition. Philadelphia, Open university press.
- Brenner MK, Rill DR, Moen RC et al., (2001):** Gene-marking to trace origin of relapse after autologous bone-marrow transplantation. *Lancet* 342: 1143-1147.
- Brown PSJR, Parenteau GL, and Dirbas FM (1991):** Anti- Tac – H, a Humanized antibody to the IL -2 receptor, prolongs primate cardiac allograft survival. *Proc Nat Acad Sci USA* 88: 2663-2667.
- Bruil, J., Maes, S., LeCoq, L., et al. (1997):** The development of the How Are You? (HAY); a quality of life questionnaire for children with a chronic illness. *Quality of life news letter* (18); 9.
- Buchsel P (1993):** Bone Marrow transplantation. In Groenwald S, Frogge M., Goodman M., *Cancer nursing: principles and practice*, 3rd ed. Boston: Jones & Bartlett, 393 -434.
- Button LN, De Well WC, Newburger PE, Jacobsen MS, Revy SV (1991):** The effects of irradiation on blood components: *Transfusion* 21: 419-424.
- Byers VS, Henslee PJ, and Kernan NA (1991):** Use of anti- pan T lymphocyte ricin A chain immunotoxin in steroid – resistant – acute graft – versus host disease *Blood* 75: 1427-1432.

- Bonomi Bonomi, A. E., Patrick, D.L., Bushnell, D.M., et al., (2000):**
Validation of the united states' version of the world health Organization Quality of life (WHOQOL) instrument. J Clin Epi 53: 1-12.
- Catherine, M.; Verfillie, E.; Martin, F.; Pera, R. and Peterm. L. (2002):** Stem cell: hope and reality American Society of hematology: (4): 112-115.
- Caudell KA (1997):** Graft versus host disease in wheldon MB and Wujcik D (Ed.). blood and Marrow stem cell transplantation, principles, practice and nursing insight. 2nd ed. Sundburg. Messachusetts. Jones & Bartlett, 177-204.
- Cella, D. (1991):** Functional status and quality of life: current views on measurement and intervention. In, functional status and quality of life in persons with cancer. Atlanta, USA, American cancer society: 1-12.
- Center for disease control update & adult immunization (1991):** Recommendations of the immunization practices advisory committee. MMWR 40 (No. RR -12): 13-15.
- Chagrui J, Lepage-Noll, Anjo A et al., (2003):** Fetal liver stroma consists of cells in epithelial-to-mesenchymal transition. Blood. 101: 2973-82.
- Chakraverty R, Peggs K, Chopra R, et al., (2002):** Limiting transplantation-related mortality following unrelated donor stem cell transplantation by using a non myeloablative conditioning regimen. Blood 99: 1071-8.
- Chan CK, Hyland RH, and Hutcheon MA (1990):** Pulmonary complications following bone marrow transplantation.

- Chapko MK, Syrjala KL, and Schilter I (1989):** Chemotherapy toxicity during bone marrow transplantation: time, course and variation in pain and nausea. *Bone marrow transplant* 4: 181-186.
- Childs R, Chernof A, Contentin N et al., (2000):** Regression of metastatic renal cell carcinoma after non myeloablative allogeneic peripheral blood stem cell transplantation. *New Eng Jour of Med* 343: 750-8.
- Choen, C.I., Teressi, J. and Holmes, D. (1987):** Social Networks and mortality in an inner city elderly population. *Int. J. ageing and Hum. Dev.* 24; 257- 269.
- Clift RA, Buckner CD, and Appelbaum T.R (1990):** Allogeneic marrow transplantation in patients with acute myeloid leukemia in 1st remission. A randomized trial of two irradiation regimens. *Blood* 76 (9): 1867-1871.
- Cogle CR, Guthrie SM, Sanders RC, Alleh WL. (2003):** An overview of stem cell research And regulatory issues. *Mayo clinic Proc.* 78 (8), 993- 1003.
- Collin BA, Leather HL, Wingard JR, Ramphal R, 2001:** Evolution, incidence, and susceptibility of bacterial blood stream isolates from 519 bone marrow transplant patients. *Clin. Infect. Dis.*, Oct. 1: 33 (7): 947-53.
- Cooke KR, Hildebrandt G (2006):** Pulmonary toxicity following haematopoietic stem cell transplantation: is the lung a target organ of graft-versus-host disease? *Curr Opin Organ transplant* (1): 69-77.
- Corradini P, Turella C, Olivieri A et al., (2002):** Reduced intensity conditoning followed by allografting of haematopoietic cells can produce clinical and molecular remission in patients with poor risk haematologic malignancies. *Blood* 99: 75-82.

- Crilley P, Lazarus H, Topolsky D. (1993):** Comparison of preparative transplantation regimens using carmustine/etoposide/ cisplatin or busulphan/etoposide/cyclophosphamide in lymphoid malignancies *semin oncol*; 20-50-4.
- Cummins, S.K. and Jackson, R. J. (2001):** The built environment and childrent's health, *ped. Clin. North. Am.* 48 (5); 1241-1252.
- Danaher EH, Ferrans CE, (2003):** Quality of life Immediately after peripheral Blood stem Cell transplantation. *Cancer Nurs.* 26(4): 312-322.
- Daninie E, (1991):** Assessment of Bone Marrow Donors. *Nurse Stand.* 5 (32): 28-31.
- De Vreese K, Barylski R, Pughe P, Blaser M, Evans C, Norton J, Semana G, Verpooten G, Hulstaert F. (2004):** Performance characteristics of updated assays for molecular typing of HLA- A, HLA- B& HLA- DRB, alleles *Clin. Diagn Lab Immunol.* 11 (2): 430- 32.
- De-Bari, C.; Dell Accio, F.; Tylzanowski, P. and Luyten, F.P. (2001):** Multipotent mesenchymal stem cells from adult human synovial membrane. *Arthritis Rheumatism*, 44: 1928-1942.
- Deeg HJ (1994):** Delayed complications after bone marrow transplantation. In *forman, SJ, Blume KG, and Thomas ED: (Eds) Bone Marrow transplantation.* Boston Blackwell scientific.
- Deeg HJ and Henslee-Downey PJ (1990):** Management of acute graft-versus-host disease. *Bone marrow transplant* 6: 1-8.
- De-Marie S (1996):** Liposomal and lipid based formulation of amphotericin b. *Leukemia* 10 (2): 93-96.
- Demeter; S.L., Smith, G.M. and Anderson, G.B. (1996):** Approaches to disability evaluation. In; *Disability evaluation* S.L. demeter, G.B.

et al smith edition. St louis Missouri, American medicine, association.

Dieterlen-Liver F, Pardanaud L, Caprioli A et al., (2001): Non-Yolk Sac haematopoietic stem cells: the approach (L1 Zon, ed.), pp. 201-8 Oxford University Press, New York.

Dimitrakopoulos I, Magopoulos C, Karakasis D (2006): Bisphosphonate-induced avascular osteonecrosis of the jaws: a clinical report of 11 cases. Int. J. oral Maxillofac Surg 2006 35(7): 588-93.

Doney KL, Leisenring W, Storb R, and Appelbaum FR (1997): Primary treatment of aquired aplastic anemia: outcomes with bone marrow transplantation and immunosuppressive therapy: Seattle Bone Marrow Transplant Team. Ann Intern Med 126: 107.

Drobyski WR. (2000): Evolving stratigies to address adverse transplant outcomes associated with T-cell depletion. J Hematother Stem Cell Res. 9(3): 327-37.

Dzierzak E and Oostendorp R, (2001): Haematopoietic stem cell development in mammals. In: Haematopoiesis: a development approach (LI Zon, ed.), pp. 209-17. oxford University Press, New York.

Egyptian Growth Charts (2002): Cairo university. Diabetic Endocrine and Metabolic Pediatric unit and the national Research Centre- Cairo, in collaboration with Wright state university school of Medicine. Department of community health. Health Research centre. From a sample size of 33189 boys & girls (birth -12ys).

Einsele H, Bertz H, Beyer J, Michael G and Others, (2004):Infections complications after allogeneic stem cell transplantation: epidemiology and interventional therapy strategies. Annals of Hematology (82): 175-185.

- Einsele H, Ehninger G, and Schneider EM (1988):*** High frequency of graft versus host like syndrome follows Syngeneic BMT. Transplantation 45: 579-585.
- Eiser, C. and Morse, R. (2001 a):*** A review of measures of quality of life for children with chronic illness. Arch Dis Child. 84, 205-211.
- Eiser, C. and Morse, R. (2001 b):*** can parents rate their child's health related quality of life? Results of a systemic review qual. Of life res. 10; 347-357.
- Eiser, C., Colter, I., Oades, P., et al., (1999):*** Health related quality of life measures for children. Int. J. Cancer S 12;; 87-90.
- Eiser; C. (1997):*** Children's quality of life measures. Arch. Dis. Child. 77; 350-354.
- EL-Lawindi, M.I. (1999):*** Health related quality of life, Essay prepared for partial fulfillment of the degree of assistant professor of public health. Kasr Elaini Cairo Univ. library.
- Elliott C, McCarthy D. (1994):*** A survey of methods of processing and storing of bone marrow & blood stem cells is in the EBMT. Bone Marrow Transplant. 14(3): 419-23.
- Ely P, Duntiz J, and Rogosheske J (1991):*** Use of Somatostatin analogue (octreotide acetate) in the management of acute gastrointestinal graft- versus- host disease Am J med 90: 707-711.
- Eppinger T, Ehninger G, Steinert M, Niethammer D, and Dopfer R (1990):*** 8 Methoxy Psorlaen and UVR A therapy for cutaneous manifestations of graft- versus- host disease. Transplantation 50: 807-811.
- Essel JH, Halvorson RD, Snyder MJ, Harman GS, and Thompson JK (1991):*** Pilot trial of ursodial to prevent veno-occlusive disease of

- the liver (VOD) associated with cyclosporine/ methotrexate (MTX) graft versus host disease.
- Fahmy SI and El-Sherbini AF (1983):** Determining simple parameters for social classification for health research. Bulletin of the high institute of P.H. Vol. XIII No. 5: 95-107.
- Falciatori, I.; Borsellino, G.; Haliassos, N.; Battistini, L.; Bernardi, G.; Stefanini, M. and Vicini, E. (2004):** Identification and enrichment of spermatogonial stem cells displaying side-population phenotype in immature mouse testis. FASEB. J., 18: 376-388.
- Feeny, D., Furlong, W., Mulheren, R.K., et al (1999):** A framework for assessing health- related quality of life among children with cancer. Int. J. cancer s12; 2-9.
- Feld R (1989):** The compromised host. Eur J canc Clin Oncol 25: 51-57.
- Ferrara JLM and Deeg HT (1991):** Mechanisms of disease: graft versus host disease. N Eng. J med 324 (10): 667-674.
- Ferrari, G.; Strornaiuolo, A. and Mavillo, F. (2001):** Failure to correct murine muscular dystrophy. Nature, 411: 1014-1015.
- Fitzpatrick, R., Fletcher, A., Gore, S., et al., (1992):** Quality of life measures in health care. I: Applications and issues in assessment BMJ 305; 1074-1077.
- Fried RH, Murakami CS, Fisher LD, Wilson RA, Sullivan KM and McDonald GB (1992):** Urosodeoxycholic acid treatment of refractory chronic GVDH of the liver. Ann Intern Med. 116: 624-629.
- Fujimaki K, Maruta A, Yoshida M, et al., (2001):** Severe cardiac toxicity in hematological stem cell transplantation: predictive value of reduced left ventricular ejection fraction. Bone Marrow transp. 2001 Feb, 27; (3): 307-310.

- Fullilove, M.T. (2001):** Links between social and physical environments. *Ped. Clin. North. Am.* 48 (5); 1253-1266.
- Gaipa G, Dassi M, Perseghin P, Venturi N, Corti P, Bonanomi S, Balduzzi A, Peters C, Rovelli A (2003):** Allogeneic bone marrow stem cell transplantation following CD₃₄⁺ immunomagnetic enrichment. *Bone marrow Transplant.* 31(10): 857-60.
- Gale, R. and Butturini A (1995):** What is the best strategy for bone marrow and blood cell autotransplant in cancer? Baltimore, Williams & wilkins, 117-199.
- Gandini G; Franchini M; Vassanelli A; et al (2002):** Immunohaematological aspects of bone marrow transplantation. *Hematology*, 7 (2): p 89-93.
- Geiger H, Sick S, Bonifer C et al., (1998):** Globin gene expression is reprogrammed in chimeras generated by injecting adult haematopoietic stem cells into mouse blastocyst. *Cell* 94: 1005-65.
- George, L.K., Blazer, D.G., Hughes, D.C., et al. (1989):** Social support and the outcome of major depression. *Brit. J Psych.* 154; 478-485.
- Ginis, I.; Luo, Y. and Miura, T. (2004):** Differences between human and mouse embryonic stem cells. *Dev. Biol.*, 12: 45-56.
- Giralt S, Estey E, Albitar M et al., (1997):** Engraftment of allogeneic haematopoietic progenitor cells with purine analog-containing chemotherapy: harnessing GVL without myeloablative therapy. *Blood* 89: 4531-6.
- Gleixner B, Klob HJ, and Holler E (1991):** Treatment of graft-versus-host disease with OKT₃: Clinical outcomes & side effects associated with release of TNF- α . *Bone Marrow Transplant* 8: 93-98.

- Gluckman E, Rocha V, Chastang C. (1998):** European results of unrelated cord blood transplants. Eurocord Group. Bone Marrow Transplant; (suppl. 3) 587-591.
- Gluckman E, Rocha V, (2002):** Factors associated with outcome if unrelated cord blood transplant: guidelines for donor choice. An Eurocord study. Blood 2002; 100 (Suppl.1): 642 a.
- Glucksberg H, storb R & Fefer A (1974):** Clinical manifestations of graft –versus host disease in human recipients of marrow from HLA- identical sibling donors. Transplantation 18: 294-304 (caught).
- Goldman J. Liesveld J, Nicholas D, Heal J, Blumerg N. (2003):** ABO incompetability between donor & receptient and clinical outcomes in allogeneic stem cell transplantation. Leuk Res. 27(6): 489-91.
- Goldman JM. (1992):** Bone marrow transplantation for acute and chronic myeloid leukemia. Leukemia 6: 22-23.
- Goodrich JM, Mori M; and Gleaves CA (1991):** Early treatment with gancyclovir to prevent CMV disease after allogeneic BMT. N Engl J Med 325: 1601-1607.
- Gordon MY (1993):** Haemopoietic growth factors and receptors: bound and free. Cnacer cells 3: 127-33.
- Gordon My, Marley SB, Davidson RJ et al., (2000):** Contact-mediated inhibition of human haematopoieitc progenitor cell proliferation may be conferred by stem cell antigen, CD34. the Haematology J 1: 77-86.
- Graf T (2002):** Differentiation plasticity of haematopoietic cells. Blood 99: 30069-101.
- Graus F, Saiz A, SierraJ, Arbaiza D aro Rozman C, (2006):** Neurologic complicatios of autologous and allogeneic bone marrow

- transplantation in patients with leukemia, a comparative study. *Neurology*; 46: 1004-1009.
- Green DM, D'Angio GJ, Beckwith JB et al., (1996):** Wilm's Tumour. *Cancer Journal for clinicians*; 46: 46-63.
- Greenbaum BH (1991):** Transfusion associated graft versus host disease: historical perspectives, incidence, and current use of irradiated blood products. *J Clin Oncol* 9: 1889-1902.
- Gronthos, S.; Mankani, M.; Brahimi, J.; Robey, P.G. and Shi, S. (2000):** Postnatal human dental pulp stem cells (DPSCs) in vitro in vivo. *Nat. Acad. Sci. USA*, 97: 13625-13630.
- Gross, T.G.; Egeler, R.M.; Smith, F. O. (2002):** Pediatric hematopoietic stem cell transplantation. *Hematol oncol. Clin. North Am* 15, 795-808.
- Grundy JE, Shanley JD, and Shearer GM (1985):** Augmentation of graft versus host reaction by cytomegalovirus infection resulting in interstitial pneumonitis. *Transplantation* 39: 548-53.
- Gulati, S. C. (1993):** Purging in bone marrow transplantation. Landes, Armstrong Printing. Austin, Tx.,
- Haddad N, Rowe JM (2004):** Current indications for reduced intensity allogeneic stem cell transplantation. *clin. Haemat.* 17: 377-86.
- Hamilton PJ and Pearson ADJ (1986):** Bone marrow transplantation and the lung. *Thorax* 41: 497-502.
- Hegland J (1997):** HLA & issues of stem cell donation. In : Wheldon MB and Wuijck D (Eds). *Blood and Marrow stem cell transplantation: principles, practice and nursing insights*. And ed. Sundburg, Massachusetts. Jones & Bartelt, 43-65.
- Hyland, M.E. (2002):** Recommendations from quality of life scales are not simple. *BMJ* 325; 599.

- Height S and Sheilds M (1995):** Problems following bone marrow transplantation, In Treleaven J and Wiernik P (Eds.) coloured atlas and text of Bone Marrow Transplantation. London: Mosby-Wolfe, 169-180.
- Helder , D. J; Baker, B.; De Heer, P.; Van der Veen, F.; Vossen, J. M.; Wit, J. M, Kaptien A. A. (2004):** Quality of life in adults following bone marrow transplantation during childhood. Bone Marrow transplant. 33(3): 329-336.
- Hoffbrand, A.V., Catovsky D., Tudenham E.G.D. (2005):** Haematology 5th edition Backwell publishing Ltd, P. 419-449.
- Hong, R.; Cooper, M. and Allan, M. J. (1968):** Immunological restitution in lymphopenic immunological deficiency syndrome. Lancet 1: 503. (Caught).
- Horwitz EM, Prockop DJ, Gordon PL et al., (2006):** Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 97 (5), 1227-1231.
- Horwitz ME, Barrelt AJ, Brown MR et al (2001):** Treatment of chronic granulomatous disease with non myeloblastic conditioning and T-cell depleted haematopoietic allograft. New Eng. T. of Med. 344: 881-8.
- Horwitz, E.; Prockop, D. and Fitzpatrick, L. (1999):** Osteogenesis imperfecta cells for caution. Nat. Med., 5: 466-7.
- Hoyt R, Szer J, Grigg A, (2000):** Events associated with the infusion of cryopreserved bone marrow and/or peripheral blood progenitor cells. Bone marrow transplant; 25 (12): 1285-7.
- Inoue,H.; Yasuda, Y; Hattorsi, K.; Shimizu, T. Matsumoto, M.; Yabe,M.; Taneka, Y., Katos (2003):** The Kinetic of immune reconstitution after cord blood transplantation in children:

- Comparison with bone marrow transplantation. *Int. J. Hematol.*; 77 (4): 399-407.
- Jacob M. van Lear, MD, Alan Tyndall, MD, (2006):** Intense Immunosuppressant and stem-cell transplantation for patients with severe rheumatic autoimmune disease: A review- *Cancer Control* 10(1): 57-65.
- Jillela AP, Britt GW, Litaker MS, et al., (2000):** ototoxicity after high-dose chemotherapy with cyclophosphamide, thiotepa, and carboplatin followed by stem cell transplantation in patients with breast cancer. *Med Oncol Nov*; 17 (4): 287-92.
- Jones R, and Burnett AK. (1992):** How to harvest bone marrow for transplantation. *J Clin Path* 1992; 45: 1053-57.
- Jones RJ, Lee KSK, and Beschorner WF (1987):** Veno-Occlusive disease of the liver following bone marrow transplantation. *Transplantation* 44: 778-783.
- Jonuleit H, Adema G, Schmitt E.(2003):** Immune regulation by regulatory T-cells: implications for transplantation. *Transpl. Immunol.* 2003; 11(3-4) 267-76.
- Juttner, C.; Fibbe, W. and Nemunaitis, J. (1994):** Blood cell transplantation: report from an international consensus meeting. *Bone Marrow Transplantation.* 34: 689-693.
- Kale, S.; Karihaloo, A.; Clark, P.R.; Kashgarian, M.; Krause, D.S. and Cantley, L.G. (2003):** Bone marrow stem cells contribute to repair of the ischemically injured renal tubule. *J. Clin. Invest.* 112: 42-49.
- Kanfer E. (1992):** The diagnosis and management of early complications. In Trebleaven J and Harreh J (Eds) *Bone Marrow transplantation in practice.* New York: Churchill livingstone. 315: 127.

- Karussis D, Kassis I, Basan GS, Slavin S. (2007):** Immunomodulation and neuroprotection with mesenchymal neuroimmunological/neurodegenerative diseases. J. Neurol Sci. paper of 15pages.
- Kawbata, Y.; Hirokawa, M.; Komatsuda, A, Sawadak, (2003):** Clinical application of CD34+ cells-selected peripheral blood stem cells. Therapy Apher Dial. 7(3): 298-304.
- Keating, (1995) A :** Autologous bone marrow transplantation. In Armitage, Antman, K. (Eds.). High -dose therapy: pharmacology, Haematopoitins, Stem cells. Baltimore: Williams & Wilkins, 172-195.
- Kennedy MS, Deeg HJ, and Storb R (1985):** Treatment of acute graft-versus host disease after allogeneic marrow transplantation: randomized study comparing corticosteroids & cyclosporine Am J Med. 78: 978-983.
- Kessinger A, Smith D & Strandjord S (1989):** Allogeneic transplantation of blood derived T-cell depleted, hemopoltic stem cells after myeloablative treatment in a patient with acute lymphoblastic leukemia. Bone marrow transplant 4: 643-646.
- Kessinger, A. (1993):** Utilization of peripheral blood stem cells in autotransplantation. Hematol Oncol Clin North Am 7(3):535-545.
- Kier P, Penner E and Bakos S (1990):** Auto-antibodies in chronic GVHD: high prevalence of antinuclear antibodies. Bone Marrow transplant 6: 93-96.
- King C, Hoffar N, and Murray M (1992):** Acute renal failure in bone marrow transplantation. Oncol Nurs Forum 19(9): 1327-1335.
- KOC O.N., Gerson SL., Cooper BW, et al., (2005):** Allogeneic mesenchymal stem cell infusion for treatment of metachromatic

- leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant. 30 (4), 215-222.
- Kirsty J, Michael P and Stephen M (2005):** Non myeloablative transplantation. Haematology 5th ed. Blackwell, 26: 436-447.
- Kirvit W, Lockman LA, Watins PA, et al., (2002):** The future for treatment by stem cell transplantation for adcenoleukodystrophy, metachromatic leukodystrophy. Globoid cell leukodystrophy and Hurler Syndrome, J Inherit Metab Dis 18: 398.
- Klastersky J (1992):** Infections in patients with cancer: prevention. In: Moose AR, Schimpff SC, and Robson MC (Eds) comprehensive textbook of oncology, vol 2 (2). Baltimore: Williams & Wilkins, 1749- 1753.
- Klein J. and Sato A (2000)** The HLA system N. Eng. J. med. 343 (1), 702- 9.
- Kletzel, M; Longino, R., Rademaker, A. W. and Danner-Koptik K.E.(1998):** Peripheral blood stem cell transplantation in young children: experience with Transplant 2(3): 191-196.
- Kolb EA, Gidwani P, Sakamoto K., other (2006):** haematopoietic stem cell transplantation, Cancer, 98 (21): 2643-50.
- Kollet, O.; Shvitiel, S.; Chen, Y.Q.; Suriawinata, J.; Thung, S.N.; et al., (2003):** HGF, SDF-1, and MMP-9 are involved in stress-induced human CD₃₄⁺ J. Clin. Invest, 112: 160-69.
- Korbling, M; Anderlini P. (2001):** Peripheral blood stem cell versus bone marrow transplantation: Does the source of hematopoietic stem cells matter? Blood. 98 (10): 2900-8.
- Kottaridis PD, Milligan DW, Chopra R et al. (2000):** In vivo campath-1H prevents graft-versus host disease following non myeloablative stem cell transplantation. Blood 96: 2419-25.

- Krause DS, Fackler MJ, Civin CI et al., (1996):** CD34 structure, biology and clinical utility. *Blood* 87: 101.
- Krishnamurti L, Blazar BR and Wagner JE (2001):** Bone marrow transplantation without myeloablation for sickle cell disease. *N Eng. J of Med.* 344: 68.
- Kumar M, Kedar a, beiberger RE (2004):** Kidney function in long-term pediatric survivor of lymphoblastic leukemia following bone marrow transplantation. *Pediat. Hem Oncol* Jul-Aug: B(4): 375-379.
- Kupari M, Violin L, and Soukas A (1990):** Cardiac involvement in bone marrow transplantation; electrocardiographic changes, arrhythmias, heart failure and autopsy findings. *Bone Marrow Transplant* 5: 91-98.
- Lankowsky, P. (2000):** Bone marrow transplantation *Manual of Pediatric Hematology and oncology* 3rd ed. Ch.25. Academic Press. 645-68.
- Larsen RL, Barber G, Heise CT, August CS,(2005):** Exercise assessment of cardiac functions in children before and after stem cell transplantation *pediatrics* 89 (4pt2): 722-729.
- Lawson SE, Roberts IA, Amrolia P, et al., (2003):** Bone marrow transplantation for B-thalassemia major: the UK experience in two pediatric centres. *British journal of hematology*, 120: 289-295.
- Lazarus HM, Rowlings PA, Zhang MJ, et al., (1999):** Autotransplants for Hodgkin's disease in patients never achieving remission: a report from the Autologous blood and Marrow transplant Registry. *J Clin Oncol*; 17: 534-545.

- Leidtke W, Quabeck K, and Beelen DW (1994):** Recurrent acute inflammatory demyelinating poly radiculitis after allogeneic bone marrow transplantation. *J Neurol Sci.* 12S: 110-111.
- Leidy, N. K. (1994):** Functional status and the forward progress of Merry- go-rounds; towards a coherent analytic frameworks. *Nurs res.* 43; 196-202.
- Leiper AD. (2002):** Non –endocrine late complications of bone marrow transplantation in childhood: part II. *Br. J. Haematology P:* 23-43.
- Leplege A, and Hunt, S. (1997):** The problem of quality of life in medicine *Jama*, 278 (1); 47-50.
- Lewalle P, Triffet A, Delforge A, Crombez P, Selleslag D, De Muynck H, Bron D & Martial P. Donor (2003):** Donor lymphocyte infusions in adult haploidentical transplant: a dose finding study. *Bone marrow transplant*, (31), 39-44.
- Lewis JL, Gordon My (2003):** Haemopoietic cytokines. In: *The cytokine Handbook*, 4th edn (EAW Thompson, MT Lotze, eds), pp. 1255-77. Elsevier Science, London.
- Li CK, Shing MM, Chik KW, Lee V, Leung TF, Cheung AY, et al., (2002):** Haematopoietic stem cell transplantation for thalassemia major in Hong Kong: prognostic factors and outcome. *Bone Marrow Transplant* 29: 101-5.
- Lucarelli G, Giardini C, Angelucci E (2004):** Bone marrow transplantation in thalassemia. *Cancer treat Res* 77: 305.
- Luijder, J.; Brown, C.; Selinger S. (1997):** Factors influencing yields of progenitor cell for allogeneic transplantation: optimization of G-CSF Dose, day of collection, and duration of leukapheresis. *Hematother, J.* 6:575-80.

- Luskin, M.B. (1993):** Restricted proliferation and migration of postnatally generated neurons derived from the forebrain subventricular zone. *Neuron*, 11: 173-89.
- Lyman SD, Mckenna HJ (2003):** Flt 3 ligand. In: *The cytokine Handbook*, 4th edn (AW Thompson, MT Lotze, eds), pp. 989-1010. Elsevier Science, London.
- Mackinnon S, Papadopoulos E, Carbasi M et al, (1995):** Adaptive immunotherapy evaluating escalating doses of donor leukocytes for relapse of chronic myeloid leukemia after bone marrow transplantation separation of GVL effect from GVHD. *Blood* 86: 1261-8.
- Maiche AG (1991):** Use of quinolone in the immunocompromised host. *Eur J Clin Microbiol. Infect. Dis.* 13: 361-367.
- Malek SN, Flinn IW. (2003):** Incorporating monoclonal antibodies in blood and marrow transplantation. *Semin Oncol.* 2003; 30(4): 520-30.
- Maramont AM, Horowitz MM, and Grale RP (1991):** T-cell depletion of HLA-identical transplants in leukemia. *Blood* 78: 2120-2130.
- Marit, G.; Thiessary, F. and Faberes, C. (1998):** Factors affecting both peripheral blood progenitor cell mobilization and hematopoietic recovery following autologous blood progenitor cell transplantation. *Leukemia*, 12(9): 1447-56.
- Martin- Rendon E, Watt SM (2003):** Stem cell plasticity. *British Journal of Haematology* 122: 877-91.
- Martin, C.M.; Meeson, A.P.; Robertson, S.M.; Hawke, T.J.; Richardson, J.A.; Bates, S.; Goetsch, S.C.; Gallardo, T.D. and Garry, D.J. (2004):** Persistent expression of the ATP-binding cassette transporter, *Abcg2*, identifies cardiac SP cells in the developing and adult heart. *Dev. Biol.*, 265: 262-275.

- Matthay KK, Villablanca JG, Seeger RC, et al., (1999):** Treatment of high-risk neuroblastoma: chemotherapy, radiotherapy, autologous bone marrow transplantation. Cancer control group. N. Eng J Med Oct 14; 341(16): 1165-73.
- May G, Enver T (2001):** The lineage commitment and self-renewal of blood stem cells. In: Hematopoiesis: a Developmental Approach (L1 Zon, ed)., pp. 61-81. Oxford University Press. New York.
- Mc Cann SR, Bacigalupo A, Gluckman E, Hintenberger W, Hows J, Ljungman P, Marin P, Nissen C, & Van't veer Kerthof E (2004):** Graft rejection & second BMT for acquired a plastic anemia: a report from the a plastic anemia working party of the European Bone Marrow Transplant Group. Bone Marrow transplantation: 13: 233-237.
- McCarthy D & Goldman J (1984):** Transfusion of circulating stem cells. CRC Crit Rev Clin Lab Sci 20(1): 1-24.
- McDonald G (1993):** Veno-occlusive disease of the liver following marrow transplantation. Marrow transplant Rev. 3 (4): 49-54.
- McNiece IK, Briddell RA (2003):** Stem cell factor. The Cytokine Handbook, 4th edn (AW Thompson, MT Lotze, eds), pp. 1011-16. Elsevier Science, London.
- McSweeney PA, Niederweisser D, Shiruzu TA et al (2001):** Haematopoietic stem cell transplantation in older patients with haematologic malignancies: replacing high dose. Cytotoxic therapy with graft versus-tumor effects. Blood 97: 3390-400.
- McSweeney P. and Storb R. (1999):** Establishing mixed chimerism with immunosuppressive, minimally myelosuppressive conditioning: preclinical and clinical studies. In: Haematology. American Society of Hematology Education Program Book, pp. 396-404.

- Medvinsky A, Smith A (2003):** Fusion brings down barriers. *Nature* 422: 823-5.
- Meller, D.; Pires, R.T and Tseng, S.C. (2002):** Ex vivo preservation and expansion of human limbal epithelial stem cells on amniotic membrane cultures. *British Journal of Ophthalmology*, 86: 463-471.
- Mellon S, Leurel L, Weiss LK, et al., (2006):** A population-based study of the quality of life of cancer survivors and their family caregivers. *Cancer Nurs.*, 29(2): 120-131.
- Messner HA & McCulloch EA (1994):** Mechanisms of human hematopoiesis. In forman SJ, Blume KG, & Thomas ED (Eds.) bone marrow transplantation. Boston: Blackwell scientific, 41-71.
- Michael S. Lee, MD, and Raj R. Makkar, MD (2006):** Stem-Cell Transplantation in Myocardial Infarction: A Status Report. *Ann Intern Med.*; 140:729-737.
- Miura, M.; Gronthos, S.; Zhao, M.; Lu, B.; Fisher, L.W.; Robey, P.G. and Shi, S. (2003):** SHED: stem cells from human exfoliated deciduous teeth *Nat. Acad. Sci. USA*, 100: 5807-5812.
- Mohle R, Bautz F, Rafii S et al., (1999):** Régulation of transendothelial migration of haematopoietic progenitor cells. *Annals of the New York Academy of Sciences* 872: 176-86.
- Moss PA, Cobbold M, Craddock C (2003):** The cellular immunotherapy of viral infections. *Transfusion Medicine* 13: 405-415.
- Muldoon; M.F., Barger, S.D; Flory, T.D., et al (1998):** What are quality of life measurements measuring? *BMJ* 316; 542-545.
- Narumi S, Shimada H, Shimasaki N, et al., (2006):** Growth-Chart based qualitative evaluation for growth in height after haematopoietic stem cell transplantation. *Pediatr transplant* 2006 (1): 26-31.

- Negrin RS and Blume KG (2001):** Allogeneic and autologous hematopoietic transplantation. Williams Hematology, 6th ed. Vol. 1, Ch. 18. New York. McGraw-Hill, 209-247.
- Nemecek ER, Mathews DC. (2003):** Use of radiolabeled antibodies in the treatment of childhood acute leukemia pediatric transplant. *Suppl* 3: 89-94.
- NG JS, Lam DS, Lick, et al., (1999):** Ocular complications of pediatric bone marrow transplantation. *Ophthalmology* Jan; 106 (1): 160-164.
- NIH Guide (1993):** In utero Stem Cell Transplantation For Genetic Diseases. Volume 22, 93-014.
- Openshaw H and Slatkin NE (1994):** Neurological complications of bone marrow transplantation. In Forman, S.J., Blume, K.G., Thomas E.D. (Eds) Bone Marrow Transplantation. Boston: Blackwell Scientific, 482-496.
- Orkin SH (2001):** Transcriptional control during erythroid and megakaryocytic development. In: Haematopoiesis: A Developmental Approach (L1 Zon, ed.), pp. 348-54. Oxford University Press, New York.
- Orlic, D.; Kajstura, J.; Chimenti, S.; Jakoniuk, I.; Anderson, S.A.; Li, B.; Pickel, J.; McKay, R.; Nadal-Ginard, B.; Bodine, D.M.; Leri, A and Anversa, P. (2001):** Bone marrow cells regenerate infarcted myocardium. *Nature*, 410-705.
- Otmar, E.; Pfister, R.; Frederic, T.; Mouquet, A.; Mohit, H.; Jain, J.; Ross G.; Summer, K.; Michiel, L.; Helmes, I.; Alan, A.; Fine, F.; Wilson, F.; Colucci, M.; Ronglih, J. and Liao, K. (2005):** CD31⁻ but not CD31⁺ cardiac side population cells exhibit functional cardiomyogenic differentiation. Whitaker cardiovascular institute, Boston university School of Medicine.

- Pantell, R. H. and Lewis, C. C. (1987):** Measuring the impact of medical care on children. *J Chron Dis.* 40; S 99-108.
- Parkman, R. (1994):** Overview: Bone Marrow Transplantation in the 1990s. *Am. J. pediatr. Hematology Oncol.* 16(1): 3-5.
- Parmer G, WuJw, Chan KW. (2003):** Bone Marrow Donation in childhood: one donor's perspective. *Psychoocology.* 12 (1): 91-4.
- Peggs KS, Mackinnon S, Williams CD et al., (2003):** Reduced – intensity transplantations with in –vivo T-cell depletion and adjuvant dose–escalating donor lymphocyte infusion for chemotherapy –sensitive myeloma: limited efficacy of graft versus tumour activity. *Biology of Blood. Marrow transplantation* 9: 257-65.
- Petersdorf EW, Hansen JA, Martin PJ (2001):** Major histocompatibility complex class I alleles and antigens in hematopoietic-transplantation. *N Engl. J Med.* 345: 1794- 800.
- Petersdorf EW, Mickelson EM, Anasetti (et al) (1999):** effect of HLA Mismatches on the outcome of hematopoietic transplants. *Current opinion in immunology* 11: 521-526.
- Petersen, B.E.; Goff, J.P.; Greeberger, J.S. and Michalopoulos, G.K. (1998):** Hepatic oval cells express the hematopoietic stem cell marker Thy-1 in the rat. *Hepatology*, 27: 433-455.
- Peterson FB and Bearman SI (1994):** Preparative regimens and their toxicity. In forman S.J., Blume, K.G., Thomas, ED (Eds.) *Bone Marrow Transplantation.* Boston Blackwell Scientific, 96-113.
- Petursson C (1993):** Bleeding due to thrombocytopenia. In Yasko JM (Ed.) *Nursing management of symptoms associated with chemotherapy*, 3rd. Philadelphia: Meniscus health care communications, 135-141.

- President's Council on Bioethics (2003):*** Human cloning and human dignity: an ethical inquiry. The president's council of Bioethics. Washington. DC, USA.
- Przepiorka D, Smith TL, Follower J.(1999):*** Risk factors for acute graft versus host disease after allogeneic blood stem cell transplantation, *Blood*; 94: 1465-72.
- Pulsipher MA, Adams RH, Asch J, Petersen FB. (2004):*** Successful treatment of JCML relapsed after unrelated allogeneic transplant with DLI and interferon alpha: evidence for a graft-versus leukemia effect in non-monosomy-7 JCML. *Bone marrow transplant.* 33 (1): 113-15.
- Quinones RR (1993):*** Hematopoietic engraftment and graft failure after bone marrow transplantation. *Am J prediator Hematol Onconl:* 15 (1): 3-17.
- Rapperport JM (1990):*** Syngeneic and autologous graft – versus- host disease: immunology, pathology and treatment. In: Burakoff SJ, Deeg HJ, Ferrara J, Atkinsonk (Eds). New York: Marcel Dekker, 455-466.
- Reece DE, Connors JM, Spinelli JJ, et al., (2000):*** Intensive therapy with cyclophosphamide, carmustine, etoposide ± cisplatin, and autologous bone marrow transplantation for Hodgkin's disease in first relapse after combination chemotherapy. *Blood*, 83: 1193-1199.
- Reynolds, B.A. and Weiss, S. (1992):*** Generation of neurons and astrocytes from isolated cells of the adult mammalian central nervous system. *Science*, 255: 1707-10.
- Rietze, R.L.; Valcanis, H.; Brooker, G.F. Thomas, T.; Voss, A.K. and Bartlett, P.F. (2001):*** Purification of a pluripotent neural stem cell from the adult mouse brain. *Nature*, 412: 736-739.

- Ringdon, O, Barrett, A. J.; Zhang, M.J.; Loberiza, F. R.; Bolwell, B. J., Cairo, M. S.; Gale R. P.; Horowitz M. M. (2003):** Decreased treatment failure in recipient of HLA. Identical bone marrow or peripheral blood stem cell transplants with high Cd³⁴⁺ cell doses. Hematol, Br. J. 121(6): 874-85.
- Robinson, D.; Ash, H.; Yayon, A.; Nevo, Z. and Aviezer, D. (2001):** Characteristics of cartilage biopsies used for autologous chondrocytes transplantation. Cell Transplant. 10: 203-208.
- Rocha V, Cornish J, Sievers E, et al. (2001):** Comparison of outcomes of unrelated bone marrow and umbilical cord blood transplants in children with acute leukemia. Blood; 97: 2962- 71.
- Ros, J.E.; Roskams , T.A.; Geuken, M.; Havinga R.; Splinter PL.; Petersen, B.R.; LaRusso, N.F.; Van, der; Kolt, D.M.; Kuipers, F.; Faber, H.J.; K.N.; Muller, M. and Jansen, P.L. (2003):** ATP binding cassette transporter gene expression in rat liver progenitor cells. Gut, 52: 1060-67.
- Rosenbaum; P., Cadman; D. and Kirpalani; H (1990):** Pediatrics: Assessing quality of life In; Quality of life assessments in clinical trials. B-spilker, (Eds). New York, Raven.
- Rosner G, Martell J, Trucco M. (2000):** Histocompatibility. In Edward D., John L, Ping L (eds) Hematopoietic stem cell therapy. 1st edition Churchill living stone, P. 225-51.
- Sarason, I. G., Sarason, B.R., and Pierce, G. R. (1999):** Social support: Global and relationship based levels of analysis, J. Soc. Press Relate. 11; 295- 312.
- Schipper, H., Clinch, J.J. and Olweny, C.L.M. (1996):** Quality of life studies; definitions and conceptual frameworks. In; quality of life and paramaloinetics in clinical trials. B. spkilker, (Eds). 2nd edition, Philadelphia, Lippincott- Raven.

- Seigel, G.M.; Sun, W.; Salvi, R.; Campbell, L.M.; Sullivan, S. and Reidy, J.J. (2003):** Human corneal stem cells display functional neuronal properties. *Molecular Vision*, 9: 159-163.
- Shah AJ, Lenarsky C, Kapoor N, Crooks GM, Kohn DB, Parkman R, Epport K, Wilson K, Weinberg K (2004):** Busulphan and cyclophosphamide as a preparative regimen for pediatric acute lymphoblastic leukemia patients undergoing bone marrow transplantation. *J pediatric Hemat Oncol*, 26 (2): 91-7.
- Sharma, A.D.; Cantz, T.; Richter, Eckert, K.; Henschler, R.; Wilkens, L.; Jochheim-Richter, A.; Arseniev, L. and Ott, M. (2005):** Human cord blood stem cells generate human cytokeratin 18-negative hepatocyte-like cells in injured mouse liver. *Am. J. Pathol.* 167: 555-64.
- Sherri S. Schultz, (2005):** Adult Stem Cell Application in Spinal Cord Injury Department of Neuroscience, Albert Einstein School of Medicine, 1300 Morris Park Avenue, Bronx, NY 10461, USA *Current Drug Targets*, 2005, 6, 63-73.
- Shih, C.C.; Weng, Y.; Mamelak, A.; LeBon, T.; Hu, M.C. and Forman, S.J. (2001):** Identification of a candidate human neurohematopoietic stem-cell population. *Blood*, 98: 2412-22.
- Shpall E, Cagnoni F, and Gehling U (1995):** Bone marrow purging in Armitage, A., Antman, K. (Eds.) *High dose cancer therapy: pharmacology, Hematopoietins, and stem cells*. Baltimore: Williams & Wilkins. 609-618.
- Shubert MM, Williams BE, and Loid ME (1992):** Clinical assessment scale for the rating of oral mucosal changes following bone marrow transplantation. *Cancer* 69: 2469-2477.
- Shuhart MC and McDonald GB (1994):** Gastrointestinal and hepatic complications in Forman, S.J., Blume, K.G., Thomas, E.D. (Eds.)

- Bone Marrow Transplantation. Boston: Blackwell scientific, 454-481.
- Shullman HM and Sullivan KM (1988):** Graft versus host disease: allo- and autoimmunity after BMT. Concepts in Immunotherapy 6: 141-165.
- Shulman HM and Hinterberger W (1992):** Hepatic veno-occlusive disease; liver toxicity syndrome after bone marrow transplantation. Bone Marrow Transplantation 10: 197-214.
- Sieberer, U.R. and Bullinger, M. (1997):** Current approaches to measure the health related quality of life in children. Quality of life news little (18); 12-13.
- Sims LC, Brecher ME, Gertis K. (2003):** In utero stem cell transplantation for genetic diseases. J Hematother. 6:213-26.
- Sklar C (1995):** Growth and endocrine disturbance after bone marrow transplantation in childhood Acta Pediatr suppl; 411: 57-61.
- Slavin S, Nagler A, Naparstek E et al., (1998):** Non myeloablative stem cell transplantation and cell therapy as an alternative to conventional bone marrow transplantation with lethal cytoreduction for treatment of malignant and non malignant haematological diseases. Blood 91: 756-63.
- Slavin S. (2003):** Graft Versus host disease, the graft versus leukemia affect, and mixed chimerism following nonmyeloablative stem cell transplantation Int. Journal hematology; 78 (3): 195-207.
- Slichter SJ (1994):** Principle of transfusion support before and after bone marrow transplantation. In: Forman SJ, Blume KG, and Thomas ED (Eds.) Bone Marrow Transplantation, Boston ! Blackwell Scientific: 110-117.
- Sloane JP, Depledge MH, and Powels RL (1983):** Histopathology of the lung after bone marrow transplantation.

- Smedler AC, Bolme P (1999):** Neuropsychological deficits in very young bone marrow transplant recipients, *Acta paediatr.* 84: 429-433.
- Smith BD, Jones RJ, Lee SM, Piatadosi S, Vala MS, Fuller D, Gore SD, Noga SJ, Ambinder RF, Miller CB. (2002):** Autologous bone marrow transplantation with 4-hydroperoxycyclophosphamide purging for acute myeloid leukemia beyond first remission: a 10-years experience. *Br J Haematol.* 117(4): 907-13.
- Snider S, Bashir R, bierman P. (2001):** Neurologic complications after high dose chemotherapy and autologous bone marrow transplantation for Hodgkin's disease. *Neurology*; 44: 681-684.
- Socie G, Salooja N, Cohen A et al. (2003):** Non malignant late effects after allogeneic stem cell transplantation. *Blood* 101: 3373-85.
- Socie G, Tone JV, Wingard TR et al (1999):** Long term survival and late deaths after allogeneic marrow transplantation: Late effects working committee of the international Bone Marrow Transplant Registry. *New Eng. Jow. of Medicine* 341: 14.
- Socinski, M.; Cannistra, S. and Elias, A. (1988):** Granulocyte-Macrophage colony stimulating factor expands the circulating haematopoietic progenitor cell compartment in man. *Lancet* 1:1194.
- Somali M, Mepatkoias V, Avramides A, et al., (2005):** Thyroid dysfunction in adults long term survivors after hematopoietic stem cell transplantation. *Horm metab Res* 2005 Aug; 37(8).
- Speiser DE, Tiercy JM, Rufer N. (1996):** High resolution HLA matching associated with decreased mortality after unrelated bone marrow transplantation. *Blood*; 87: 4455- 65.
- Spiegel, D. (1999):** Healing words: Emotional expression and disease outcome. Editorial. *JAMA* 281; 1328.

- Spilker, B (1996):** Quality of life and pharmacoeconomics in clinical trials. 2nd edition. Philadelphia, lippincott-Raven.
- Spirito, A., Delawyer, D.D. and stark, L. J. (1991):** Peer relations and social judgement.
- Staniszewska, S. (1998):** Measuring quality of life in the evaluation of health care. Nursing standard 12 (7) 36-39. Http: // www. Nursing- standard. Co. uk/ archives/ vol 12-17/ research. Html retrived July 8/2001.
- Storb R, Weiden PL, Sullivan KM et al., (1987):** second marrow transplants in patients with aplastic anemia rejecting the 1st graft: use of a conditioning regimen including cyclophosphamide and antithymocyte globulin. Blood 70: 116-21.
- Storek, J.; Gooley, T. and Siadek, M. (1997):** Allogeneic Peripheral blood stem cell transplantation may be associated with a high risk of Chronic GVHD. Blood 90:4705.
- Strasser, S. I; Sullivan, K. M.; Myerson, D. (1999):** Cirrhosis of the liver in long-term marrow transplant survivors. Blood; 93 (10): 3259-66.
- Sullivan K, Kopecky KJ, and Jocom J (1990):** Immunomodulatory and antimicrobial Efficacy of intravenous immunoglobulin in bone marrow transplantation. N Eng J Med. 323: 705-712.
- Sullivan KM and Shulman HM (1989):** Chronic graft- versus – host disease, obliterating bronchiloitis & graft –versus– leukemia effect: case histories. Transplant proc 21: 51-62.
- Sullivan KM, Storek J. and Kopecky KJ (1996):** A randomized trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic GVHD after marrow transplantation. Blood Marrow transplant 2: 44.

- Sullivan KM, Witherspoon RP and Storb R (1988):** Prednisone & azathioprine compared with prednisone & placebo for treatment of chronic GVHD: prognosis. *Blood* 72: 546-554.
- Swain, M. (2001):** Health-related quality of life (HRQOL) in viral hepatitis. Hepnet <http://www.Hepnet.Com/update18.Html> retrieved January 30.
- Symington FW, Pepe MS, Chen AB, and Deliganis A (1992):** serum tumour necrosis factor-alpha associated with acute GVHD in humans. *Transplantation* 50: 518-520.
- Syrigala Karen PHD, Collaborators (2007):** Sexual function affected by stem cell transplant, according to long term study. *American society of Hematology* (21): 114-116.
- Tanner J.M. (1962):** Growth at adolescence. 2nd edn. Oxford: Blackwell.
- Tarella, C.; Zallio, F.; Carracciolo, D. (1999):** Hematopoietic progenitor cell mobilization and harvest following an intensive chemotherapy debulking in lymphoma patients. *Stem cells*; 17 (1): 55-61.
- Taylor, E.J, Jones, p. and Burns, M. (1998):** Quality of life in Chronic illness; impacts and interventions, I.M Lubkin and P.D. Larson (Eds) 4th. Boston- USA, Jones & Barrette; 207-223.
- Testa, M.A. and Simonson, D.C. (1996):** Assessment of Quality of life outcomes *N. Eng. J. med* 334 (13); 835-840.
- Thomas ED, Sanders JE and Flournog N (1997):** Marrow transplantation for patients with acute lymphoblastic leukemia in remission. *Blood* 54: 468-476.
- Thomson AW, Lotze MT (eds) (2003):** The Cytokine Handbook, 4th edn, pp. 1255-77. Elsevier science, London.
- Thorgeirsson, S.S. (1996):** Hepatic stem cells in liver regeneration. *FASEB. J.*, 10: 1249-56.

- Thyndall and furst (2007):** Stem cell transplantation of autoimmune disease: progress and problems. *Curr Opin Rheumatol.* 14: 220-224.
- To, L.; Shepperd, K. and Haylock (1990):** Single dose of cyclophosphamide enable the collection of high numbers of hematopoietic stem cells from peripheral blood. *Exp Hematol* 18:442.
- Tollemar J, Ringden O, and Anderson S (1993):** Prophylactic use of liposomal amphotericin B (ambisome) against fungal infections: a randomized trial in bone marrow transplant recipient. *Transplant Proc* 25: 1495: 1497.
- Treleaven J and Wiernik P (1995):** Coloured Atlas and text of bone marrow transplantation.
- Turner, J. and Kelly, B. (2000):** Emotional dimensions of chronic disease. *West J Med* 172; 124-128.
- Tutschka PJ, Teasdall R, Beschorner WE, Santos GW (1982):** Chronic GVHD in the rat. *Transplantation* 34: 289-294.
- Tzukerman, M.; Rosenberg, T.; Ravel, Y.; Reiter, I.; Coleman, R. and Skorecki, K. (2003):** An experimental platform for studying growth and invasiveness of tumor cells within teratomas derived from human embryonic stem cells. *Proc. Natl. Acad. Sci. USA.*, 100 (23): 13507-12.
- Ueno NT, Cheng YC, Randon G et al., (2003):** Rapid induction of complete donor chimerism by the use of a reduced intensity conditioning regimen composed of fudarabine and melphalan in allogeneic stem cell transplantation for metastatic solid tumors. *Blood* 102: 3829-36.

- Varni JW, Seid M, Kurtin PS (2004):** Pediatric health-related quality of life measurement technology: A guide for health care decision makers. *Cancer version*. 82: 1184-1196.
- Vaughn MD, Rowland CC, Tong X, et al., (2005):** Dental abnormalities after pediatric bone marrow transplantation. *Bone marrow transplant* 2005 Oct; 36(8): 725-729.
- Veit, C.T., Ware, J.E., (1993):** The structure of psychological distress and wellbeing in general populations. *J. consul. Clin. Psychol.* 51 (5); 730-742.
- Verdonck LF, Cornelissen JJ and Smith J (1993):** Successful foscarnet therapy for acyclovir resistant mucocutaneous infection with herpes simplex virus in a recipient of allogeneic bone marrow transplantation. *Bone marrow transplantation* 11: 177-179.
- Verfaillie CM (2001):** Ex vivo expansion of stem cells. In: *Hematopoiesis: A Developmental Approach* (L1 Zon, ed.), pp. 119-29. Oxford University Press, New York.
- Vogelsang GB, Farmer ER, and Hers AD (1992):** Thalidomide for treatment of chronic graft- versus - host disease. *New Eng J Med*. 326: 1055-1058.
- Wade JC (1992):** Infections in patients with cancer: treatment. In Moosa AR, Schimpff SC, and Robson MC (Eds). *Comprehensive text book of oncology*. Philadelphia: Williams & Wilkins, 1740-1748.
- Wagner JE, Barker JN, De For Te et al., (2002):** Transplantation of unrelated donor umbilical cord blood in 102 patients with malignant and nonmalignant diseases: influence of CD₃₄⁺ cell dose & HLA disparity on treatment-related mortality & Survival. *Blood*; 100:1611-1618.

- Wallerstein R and Deisseroth A (1993):** use of blood and blood products in De Vita, principles and practice of Oncology. Philadelphia: J.B. Lippincot, 2262-2275.
- Walters MC, Thomas ED (2001):** Bone Marrow transplantation for thalassemia, the USA experience. Am J pediatr Hematol Oncol 16: 11.
- Ware, J.E. (1984):** Conceptualizing disease impact and treatment outcomes. Cancer 53; 2316-2326.
- Weisdorf D, Haake R, Blazer B (1991):** Risk factors of acute graft-versus host disease in histocompatible donor bone marrow transplantation 51: 1197-1203.
- WHO (1980):** International classification of impairments, disabilities and handicaps. World health organization, Geneva, Switzerland.
- WHO (1993):** Measuring quality of life, the development of the world health organization Quality of life instrument. WHO –QOL group. Geneva, Switzerland.
- WHO (1996):** WHOQOL-BREF: introduction, administration scoring and generic version of the assessment. Field trial version. WHO programme on mental health, Geneva, Switzerland.
- Wingard JR, Paintadosi S, and Vogelsang GB (1989):** Predictors of death from chronic graft-versus-host –disease after bone marrow transplantation blood 74: 1428-1435.
- Wingard JR (1990)a:** Advances in the management of infectious complications of bone marrow transplantation. Bone Marrow transplantation 6: 371: 383.
- Wingard JR, Mellits ED, and Sostrin MB (1988):** Interstitial pneumonia after allogeneic bone marrow transplantation: nine years experience at a single institution. Medicine 67: 175-186.

- Wingard JR (1990)b:** Management of infectious complications of bone marrow transplantation. *Oncology* 4 (2): 69-75.
- Witherspoon RP, Sulliran KM, and lum LG (1988):** Use of thymic grafts or thymic factors to augment immunologic recovery after Bone Marrow transplantation: brief report with 2-12 years follow up. *Bone Marrow transplant* 3: 425-435.
- Wujcik D, Ballard B, and comp-Correll D (1994):** Selected complications of allogeneic bone marrow transplantation. *Semin Oncol Nus* 10 (1): 28-41.
- Yeager Am (1990):** Ex vivo Chemopurging of autologous bone marrow with 4-hydroperoxycyclophosphamide to eliminate occult leukemic cells: Laboratory and Clinical Observations. *Am. J. Pediatr Hematology/Oncology*; 12:245-56.
- Yoshihara T, Naya M, Tsunamotok, Hojo M, Hibi S, Morimoto A, Todo S, Imashuku S. (2003):** A preparatory regimen of total body irradiation, busulphan and melphalan for allogenic bone marrow transplantation in childhood high risk leukemia and lymphoma. *Anticancer Res.*; 23 (2C): 1739-42.
- Zecca M, Prete A, Rondelli R. (2002):** Chronic graft versus host disease in children: incidence, risk factors, and impact on outcome. *Blood*, 100: 1192-1200.
- Zerbe M, Parkerson S, and Spitjer T (1994):** Laminar air flow versus reverse isolation: nurses, assessments of moods, behaviors and activity levels in patients receiving bone marrow transplants. *Oncol Nurs forum* 21 (3): 565-568.
- Zuk, P.A.; Zhu, M.; Ashjian, P.; De Ugarte, D.A.; Haung, J.I.; Mizuno, H.; Alfonso, Z.C.; Fraser, J.K.; Benhaim, P. and Hedrick, M.H. (2002):** Human adipose tissue is a source of multipotent stem cells. *Mol. Biol. Of the Cell*, 13: 4279-4295.